News

Novo Nordisk A/S (NVO): A Bull Case Theory
We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will ...
STAT5h
Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game
Novo Nordisk is seen as having fallen behind in the race for new obesity drugs. It argues it is playing the long game.
Healthy Returns: New weight loss drug data show Eli Lilly is gaining ground
Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...
How to Invest in Ozempic
Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.
Novo Nordisk A/S (NVO): “How Could They Be So Far Behind?,” Wonders Jim Cramer
Novo Nordisk A/S (NYSE:NVO) is one of the Jim Cramer Reveals Potential US Rare Earth Trump Card & Discusses These 11 Stocks.
BioSpace10h
Prescription Drug Sales Will Hit $1.75T By 2030 Thanks to GLP-1s: Evaluate
Eli Lilly’s tirzepatide is expected to be worth $62 billion annually by 2030, according to Evaluate. That valuation would be ...
New data shows just how powerful the next weight-loss drugs may be
If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...
Novo Nordisk: End to Telehealth Collaboration, Mixed Amylin Data Weigh on Valuation
Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...
After key conference, here's how the race to a $150 billion weight-loss drug market is shaping up
With patents expiring and the obesity market opening up, major players in the weight-loss market are lining up to see what will follow the likes of Wegovy and Zepbound. With Morgan Stanley estimating ...